Global Automated Cell Counting Market is valued at approximately USD 3.01 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 12.45% during the forecast period 2023-2030. Automated cell counting is a sophisticated laboratory technique that utilizes advanced technology and image analysis algorithms to accurately quantify the number of cells in a biological sample. This method eliminates the need for manual counting, which can be time-consuming and prone to human error. In automated cell counting, a specialized instrument, often a cell counter or automated microscope, captures images of the cells in a sample. The Automated Cell Counting Market is expanding because of factors such as increased prevalence of chronic diseases, expansion of biopharma research and development (R&D), and government initiatives to promote research related to cell therapies.
The escalating prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions serves as a significant catalyst for the advancement of the Automated Cell Counting Market. As reported by the World Health Organization (WHO), diabetes alone accounted for 1.5 million deaths in 2021, while cancer was directly responsible for 10 million deaths globally. The ongoing monitoring requirements for blood cell counts in the context of chronic diseases propel the demand for automated cell counters. These automated systems enhance the efficiency and accuracy of cell counting processes in diagnostic laboratories, research institutions, and hospitals. With their high-throughput capabilities, these automated cell counters can meticulously assess substantial sample volumes, contributing to precise diagnosis and monitoring for individuals grappling with chronic diseases. The GLOBOCAN 2020 report estimates that there were roughly 19,292,789 new cases of cancer worldwide in 2020. By 2040, there would likely be 28,887,940 instances, according to projections. Additionally, according to the IDF Diabetes Atlas Tenth Edition 2021, about 537 million adults worldwide were discovered to have diabetes in 2021, with estimates showing that figure would rise to 643 million by 2030 and 783 million by 2045. Thus, the rising prevalence of chronic diseases is driving the market growth. In addition, applications of cell counting in personalized medicine and growth in stem cell research are creating new opportunities for market growth. However, the high cost of Automated Cell Counting stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Automated Cell Counting Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. In the year 2022, North America emerged as the dominating region in the market, driven by various pivotal factors such as the rising incidence of cardiovascular and chronic diseases, substantial healthcare spending, and technological progress within the region. Conversely, the Asia Pacific region is positioned for significant expansion in the coming years. This anticipated growth is fueled by the increasing prevalence of chronic diseases, augmented investments in healthcare, and proactive governmental engagement in drug development initiatives in the region.
Major market player included in this report are:
Thermo Fischer Scientific Inc.
Countstar, Inc.
Bio-Rad Laboratories, Inc
F. Hoffmann-La Roche Ltd
Chemometec A/S
Danaher Corporation
Olympus Corporation
MERCK KGaA
Sysmex Corporation
Agilent Technologies, Inc.
Recent Developments in the Market:
Ø In October 2023, The DeNovix CellDrop Automated Cell Counter attained ACT Label certification from My Green Lab, marking a significant milestone as the first approved automated cell counter under the program.
Ø In October 2022, Thermo Fisher Scientific unveiled advanced closed and automated solutions for cell isolation and bead removal, contributing to the advancements in cell therapy manufacturing. This innovative technique enhances cell purity, improves isolation effectiveness, and increases target cell recovery, thereby facilitating scalable manufacturing processes for cell therapy.
Global Automated Cell Counting Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Product, Application, End Use Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Instruments
Consumables & Accessories
By Application:
Blood Analysis
Stem Cell Research
Cell Line Development
Others
By End Use:
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Research & Academic Institutes
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa